CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
Jorge J CastilloJoshua N GustineKirsten MeidCatherine A FlynnMaria G DemosMaria L GuerreraCristina JimenezAmanda KofidesXia LiuManit MunshiNicholas TsakmaklisChristopher J PattersonLian XuGuang YangZachary R HunterSteven P TreonPublished in: American journal of hematology (2020)